Theremia is our startup of the day, winner of the ranking We innovate 500 2025, where she occupies 109th place.
Theremia is a French Deeptech which intends to redefine the way in which medical treatments are prescribed. By combining artificial intelligence, pharmacology and data sciences, it has designed a platform capable of adjusting therapies to the physiological characteristics specific to each patient. The objective: optimize the effectiveness of treatments while limiting side effects, essential lever to guarantee therapeutic observance.
A critical issue for public health
Traditional medicine is based on standardized treatments, often calibrated for average patient profiles. This approach shows its limits: almost 60 % of patients interrupt their treatment, for lack of tangible results or because of undesirable effects. Theremia offers an alternative: a fine customization of therapeutic parameters (dosage, frequency, formulation) thanks to multi-scale models doped at AI. Result: better tolerated, better targeted and potentially more effective treatments.
A rigorous scientific approach
Theremia technology mixes biomedical modeling, machine learning and pharmacokinetics. The team collaborates closely with specialists in complex pathologies of the central nervous system (Parkinson, Alzheimer, depression, multiple sclerosis), to adjust algorithms to clinical reality. This permanent interaction between researchers and practitioners guarantees the scientific relevance of the personalized treatments offered by the startup.
Added value for drug manufacturers
Its technology facilitates the collection of real life data (Real World Data), a central element of value-based approaches (“Value-Based Healthcare”). It thus allows laboratories to better convince regulatory authorities, insurers and patients of the relevance of their solutions.
A duo of founders with crossed expertise
Theremia is co -founded and directed by Iris Maréchalformer consultant at BCG specializing in public health, and Chloé Geoffroypharmacist, engineer and doctor in neuroscience. At the head of a team of ten scientists and engineers, they orchestrate the technological and medical development of the platform, with the ambition to bring out a new generation of tailor-made treatments.
A fundraising to structure acceleration
The startup finalized last fall a lifting of 3 million euros in priming, in a tour led by Eurazeo And Salica Investmentsjoined by FIRST entrepreneur,, Bpifrance and several Business Angels of the sector.
